AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.
Petru Nicolaescu
Health
Unsplash.com
Always see our news on Google
The acquisition of Fusion Pharmaceuticals by AstraZeneca brings innovative new treatments to the company's portfolio. Radioconjugates developed by Fusion are an alternative to chemotherapy and radiotherapy, minimizing damage to healthy cells. The most advanced treatment, FPI-2265, is for patients with metastatic prostate cancer.
Latest News
23:02
SANITAS calls for higher salaries in 2027, a new pay law and the removal of restrictions in healthcare
22:54
The US imposes new sanctions on companies and individuals in India and Turkey over ties to Iran and shipments of Iranian oil
22:53
A Romanian worker died aboard a ship under construction in Italy
22:42
Florin Manole announces pension increases from January 1 and a second installment of aid for pensioners with low incomes
22:23
Donald Trump warns Democrats that their party will be “destroyed” if they try to impeach him after taking control of Congress
See more news
NEWS ON THE SAME TOPICS
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
International
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
